Investors

Home / Investors / Press Releases

Press Releases

28Nov

CymaBay Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference

10Nov

CymaBay to Host Key Opinion Leader Meeting on Primary Biliary Cholangitis in New York City

10Nov

CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 for the Treatment of Primary Biliary Cholangitis

9Nov

CymaBay Reports Third Quarter 2016 Financial Results

9Nov

CymaBay Therapeutics Announces a Newly Issued U.S. Patent for the Use of MBX-8025 as a Treatment for Primary Biliary Cholangitis (PBC)

2Nov

CymaBay to Announce Third Quarter 2016 Financial Results on Wednesday, November 9

20Oct

CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting

20Oct

CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines (PRIME) Designation for the Treatment of Primary Biliary Cholangitis

11Oct

CymaBay Therapeutics Announces a Newly Issued U.S. Patent for MBX-8025 for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)

6Oct

CymaBay Therapeutics Announces an Oral Presentation Describing the Efficacy of MBX-8025 in a Preclinical Model of NASH at the AASLD 2016 Liver Meeting

RSS
Show All

Contact Info

  • 7575 Gateway Blvd., Suite 110
    Newark, CA 94560
  • +1 (510) 293-8800
  • +1 (510) 293-9090

Quick Links

Pipeline